Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis

Overview of attention for article published in Arthritis Research & Therapy, December 2019

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 19 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 3 X users, with an upper bound of 5,359 followers.

RT @UABRheum: Congrats @RADoctor ! Published in @ArthritisRes @uabmedicine @UABSOM @UABNews https://t.co/dQocRvaul9

Reply Repost Favourite

Congrats @RADoctor ! Published in @ArthritisRes @uabmedicine @UABSOM @UABNews

Reply Repost Favourite

(2/2) Cost over time for #biosimilar #infliximab in recent paper with @RheumKay https://t.co/k2beGdySwK https://t.co/kdIx6j9idD

Reply Repost Favourite

In our newest #uabrheumatology paper published, we found substantial cost reductions over time for #biosimilar #infliximab in the U.S. Despite frequent dose escalation, biosimilar savings offset doses up to (but not including) 10mg/kg.https://t.co/k2beGdyS

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.